Search Results for "Cancer Diagnostics"

04:45 EDT 25th October 2014 | BioPortfolio

Original Source: Lab21 Launches New Lung Cancer Diagnostic Service

Cambridge, UK – 16 February 2012 - Lab21 Limited, the global specialist in personalised medicine and clinical diagnostics has launched a new Companion Diagnostic testing service for non-small cell lung cancer patients. The EML4-ALK companion diagnostic test for translocations in the ALK gene will allow physicians to select lung cancer patients likely to respond to ALK inhibitor therapy. The test uses proprietary PCR technology and will be performed in Lab21’s accredited laboratories in ...

Matching Channels


Roche is the 5th largest pharmaceutical company in the world, based on annual sales, which were recorded at $36,017m in 2009. The pharmaceutical products of Roche are major players in the followin...

Penile Cancer

Laryngeal Cancer

Nasopharyngeal Cancer

Rectal cancer

Matching News

PDI subsidiary Interpace Diagnostics enters molecular diagnostics market with thyroid and pancreatic cancer test portfolio acquisition

PDI, a leading healthcare commercialization company, announced that its Interpace Diagnostics subsidiary has entered the expanding cancer molecular diagnostics market with the acquisition of the miRIn...

Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets

(PRWEB) July 29, 2014 The “Tissue Diagnostics Market by Technology (Immunohistochemistry, in Situ Hybridization, Digital pathology & Workflow, Special Staining), Disease (Breast Cancer, Ga...

GeneNews raises $Cdn7.2mm through private placement

GeneNews Ltd. (molecular diagnostics for cancer) grossed $Cdn7.2mm ($6.7mm) through the private sale of 7mm common shares at $Cdn1.03, a 13% discount. The company will use the proceeds to help its US-...

Asuragen signs cancer panel deal with Janssen Diagnostics

Asuragen has agreed to make its SuraSeq next-generation sequencing cancer panels available to Janssen Diagnostics' customers  -More- 

Memorial Sloan Kettering Cancer Center, Quest Diagnostics partner for cancer tests

Memorial Sloan Kettering Cancer Center, the world's oldest and largest private cancer center, and Quest Diagnostics, the world's leading provider of diagnostic information services, today announced a ...

Novel 'designer' nanodevice could improve cancer diagnostics, treatment

Cancer diagnostics and treatment options could be drastically improved with the creation of a 'designer' nanodevice being developed by researchers from the UK, Italy, the US and Argentina.

Cancer diagnostics company offers therapy reimbursement info for busy docs

Personalized medicine player MolecularHealth is adding an interesting reimbursement twist to its cancer diagnostics offerings: It figures out insurance options not only for the tests it offers, bu...

Accelerating the development of new cancer therapies; Ketil Widerberg, General Manager, Oslo Cancer Cluster

Four out of ten people will be diagnosed with cancer during their life and it is crucial to develop new diagnostics and medication. Oslo Cancer Cluster is an oncology research and industry cluster de...

Matching PubMed Articles

Innovations in Cervical and Endometrial Cancer.

The S2k guideline "Diagnostics and Therapy for Cervical Cancer" published in 2008 is currently being revised to the S3 level. Current developments in epidemiology, surgical therapy, radiochemotherapy ...

Structured diagnostics and therapy of the CUP syndrome.

In the majority of cases, patients with cancer of unknown primary (CUP) have a poor prognosis with no prospect of being cured. Hence, a reasonable focus of diagnostics on its essential targets seems a...

From the guest editor: into the era of personalized cancer diagnostics.

Criteria of the molecular pathology testing of lung cancer.

From the aspect of the contemporary pathologic diagnostics of lung cancer the tissue obtained is a key issue since small biopsies and cytology still play a major role. In the non-small cell lung cance...

Predictions for the future of kallikrein-related peptidases in molecular diagnostics.

Kallikrein-related peptidases (KLKs) form a cancer-related ensemble of serine proteases. This multigene family hosts the most widely used cancer biomarker that is PSA-KLK3, with millions of tests perf...

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement